WINTON GROUP Ltd Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

WINTON GROUP Ltd bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,521 shares of the company's stock, valued at approximately $1,027,000.

Other institutional investors have also modified their holdings of the company. Caprock Group LLC acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $236,000. Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company's stock worth $104,089,000 after purchasing an additional 15,266 shares in the last quarter. Tri Ri Asset Management Corp acquired a new stake in Neurocrine Biosciences in the third quarter valued at about $3,236,000. Oakworth Capital Inc. purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $379,000. Finally, Synergy Asset Management LLC acquired a new position in Neurocrine Biosciences during the 4th quarter worth approximately $996,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NBIX has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a research note on Wednesday, March 26th. Needham & Company LLC restated a "hold" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Guggenheim reduced their price objective on Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a report on Monday, February 10th. UBS Group upped their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a "buy" rating in a report on Thursday, January 30th. Finally, Canaccord Genuity Group cut their price target on Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $165.38.

Remove Ads

Neurocrine Biosciences Trading Down 2.9 %

Shares of NASDAQ NBIX traded down $3.11 on Thursday, reaching $105.20. 435,744 shares of the company traded hands, compared to its average volume of 986,344. The company has a 50 day moving average of $121.97 and a 200 day moving average of $124.66. Neurocrine Biosciences, Inc. has a fifty-two week low of $104.32 and a fifty-two week high of $157.98. The stock has a market capitalization of $10.49 billion, a PE ratio of 31.98, a P/E/G ratio of 0.77 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences declared that its board has approved a stock repurchase plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Insider Activity at Neurocrine Biosciences

In related news, insider Julie Cooke sold 1,740 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.89, for a total value of $266,028.60. Following the transaction, the insider now owns 18,202 shares in the company, valued at approximately $2,782,903.78. This trade represents a 8.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kevin Charles Gorman sold 5,844 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now owns 521,618 shares of the company's stock, valued at approximately $60,867,604.42. This represents a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 232,906 shares of company stock worth $33,869,030. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.